Radhika Tripuraneni - 10 Mar 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Jennifer Tousignant, Attorney-in-fact
Issuer symbol
VRDN
Transactions as of
10 Mar 2025
Net transactions value
$0
Form type
4
Filing time
12 Mar 2025, 16:36:26 UTC
Previous filing
03 Feb 2025
Next filing
12 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +310,700 $0.000000 310,700 10 Mar 2025 Common Stock 310,700 $15.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% on March 10, 2026 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.